Professor Yong-Jie Lu

Professor Yong-Jie Lu

MBBS, MD, PhD
Centre: Molecular Oncology
Professor of Molecular Oncology
This email address is being protected from spambots. You need JavaScript enabled to view it.

QMUL Directory


We aim to identify genetic alterations that influence the development, progression and therapeutic responses of male urogenital tumours, in particular prostate cancer, and further develop them into biomarkers for cancer diagnosis and therapeutic stratification as well as therapeutic targets for novel forms of therapeutic approaches.

Research Details

I have set up a research team devoted to genetic studies and biomarker development in male urological cancers, in particular prostate cancer. The mission of the research team is to reduce motility and morbidity of patients with male urological cancers by facilitating precision medicine through the identification of biomarkers and therapeutic targets and the development/application of novel approaches in biomarker analysis and cancer therapy.

Our past work have been mainly focused on identification of genetic alterations and genetic mechanisms in cancer development, progression and therapeutic response. Recently, our research work moved into circulation biomarker development, in particular CTCs, for cancer diagnosis, prognosis and prediction/monitoring of cancer progression and therapeutic response.

There are currently two main research areas of interest:

1. Biomarker discovery and clinical applications, focusing on circulating biomarkers (CTCs, exosomes and other cancer associated circulating cells) for cancer diagnosis, prognosis and prediction/monitoring of cancer progression and therapeutic response.

2. Genetic investigation of the mechanisms of prostate cancer metastasis and the development of novel therapeutic approaches.

Members of the lab:

Postdoctoral researchers: Xueying Mao and Elzbieta Stankiewicz

Research technician: Edwina Burke

PhD students: Tanyu Guo and Yeuzhou Zhang

Profile

Education

  • 1992 - 1995: Ph.D. student in Chinese Academy of Medical Sciences (CAMS) &  Peking Union Medical College (PUMC), Beijing. (Pathophysiology)
  • 1989 - 1992: Post-graduate student in Dept. of Biology, Harbin Medical University. (M.D. Medical Genetics.)
  • 1984 - 1989: Undergraduate medical student in Faculty of Medicine, Henan Medical University.

Appointments

  • Oct 2017- present: Professor of Molecular Oncology, Barts Cancer Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London
  • July 2010 - Sept 2017: Reader (Team Leader), Barts Cancer Institute, Barts and London School of Medicine and Dentistry, Queen Mary University of London (QMUL)
  • Jun 2003 - July 2010: Senior Lecturer (Team Leader), Barts Cancer Institute, Barts and London School of Medicine and Dentistry, QMUL.
  • Oct 2001 - Jun 2003: Research Associate (deputy Team Leader), Molecular Cytogenetics Laboratory, The Institute of Cancer Research (ICR), Sutton, UK.
  • Apr 2000 - Oct. 2001: Senior postdoctoral scientist, Molecular Cytogenetics Laboratory, Section of Paediatrics (joint with Section of Molecular Carcinogenesis), ICR, Sutton, UK.
  • Apr 1997 - Apr 2000: Postdoctoral scientist, Molecular Cytogenetics Laboratory, Section of Cell Biology & Experimental Pathology, ICR, Sutton, UK.
  • Oct 1995 - Jan 1997: Visiting Scholar, Molecular Cytogenetics Laboratory, ICR, Sutton, UK.

Funding

2017-208 Angle Europe PLC

The prognostic value of circulating megakaryocytes for cancer patients. £201,685

2017-2018 Angle Europe PLC "Evaluation of a size-based circulating tumour cell isolation system, Parsortix, for its application in prostate cancer"
£78,000
2015-2018

The Orchid Cancer Appeal

Circulating tumour cell study and biomarker identification in prostate cancer. £485,000
2015-2017 Angle Europe PLC "Evaluation of a size-based circulating tumour cell isolation system Parsortix, for its application in prostate cancer. £143,000
2010-2015 The Orchid Cancer Appeal Systematic studies of genetic alterations and identification of genes involved in male urological tumour development and progression. £792,000
2009-2012 Association for International Cancer Research Genetic and functional investigation into the role of ZDHHC14 in human tumour development. £192,685
2008-2011 Medical Research Council Identification of recurrent chromosome breakpoints and associated genes in prostate cancer using a novel approach. £303,225
2008-2010 The Orchid Cancer Appeal Systematic studies of genetic alterations and identification of genes involved in male urological tumour development and progression. £301,210
2015 The Orchid Cancer Appeal "Prostate cancer prognostic biomarker and circulating biomarker studies"
£172,000

2014

The Orchid Cancer Appeal * "Systematic studies of genetic alterations and identification of genes involved in male urological tumour development and progression"
£174,000
2013 The Orchid Cancer Appeal (As above*)
£172,000

2012

The Orchid Cancer Appeal (As above*)
£172,000

2011

Prostate Action

Confirmation of TCBA1 (NKAIN2) as a candidate tumour suppressor gene at 6q region in prostate cancer
£59,140
2011-2014 Queen Mary College Funds PhD Studentship: "Novel approach for prostate cancer therapy using TMPRSS2 promoter activity"
£62,000

2010

The Orchid Cancer Appeal

(As above*)
£171,680

2010

(As above*)
£164,080
2010-2013 Medical Research Council Industrial Case PhD Studentship (Joint application with Tom Powles): "The role of Src and its inhibition in urological cancers"
£75,000

2009

The Orchid Cancer Appeal

Yearly Award 2009/10
£157,210

2009

Association for International Cancer Research

The role of ZDHHC14
£192,685

2008

Medical Research Council

Associated genes in prostate cancer
£303,225

2008

The Orchid Cancer Appeal

CA Genetics Project 08/09
£182,420

Key Publications

Xu L, Mao X, Guo T, Chan PY, Shaw G, Hines J, Stankiewicz E, Wang Y, Oliver RTD, Ahmad AS, Berney D, Shamash J, Lu YJ. The novel association of circulating tumor cells and circulating megakaryocytes with prostate cancer prognosis. Clin Cancer Res. 23(17):5112-5122; 2017. PMID: 28615267

Xu L, Mao X, Imrali A, Syed F, Mutsvangwa K, Berney D, Cathcart P, Hines J, Shamash J, Lu YJ. Optimization and evaluation of a novel size based circulating tumor cell isolation system. PLoS ONE 10(9): e0138032; 2015. PMID: 26397728

Coll Bastus N, Mao X, Young BD, Sheer D, Lu YJ. DNA replication-dependent induction of gene proximity by androgen. Hum Mol Genet. (2015) 15;24(4):963-71. PMID: 25281662

Yeste-Velasco M, Mao X, Grose R, Kudahetti SC, Lin D, Marzec J, Vasiljević N, Chaplin T, Xue L, Xu M, Foster JM, Karnam SS, James SY, Chioni AM, Gould D, Lorincz AT, Oliver RT, Chelala C, Thomas GM, Shipley JM, Mather SJ, Berney DM, Young BD, Lu YJ. Identification of ZDHHC14 as a novel human tumour suppressor gene. J Pathol. (2014) 232(5):566-77. PMID: 24407904


Further Publications

For additional publications, please click here.


We aim to identify genetic alterations that influence the development, progression and therapeutic responses of male urogenital tumours, in particular prostate cancer, and further develop them into biomarkers for cancer diagnosis and therapeutic stratification as well as therapeutic targets for novel forms of therapeutic approaches.

External Activities

  • Senior Editor: American Journal of Cancer Research
  • Editorial Board Member: The Open Breast Cancer Journal.
  • Editorial Board Member: Journal of Cancer Research Updates.
  • Scientific assessment committee member: France national cancer research programme Canceropole (2007-2014).
  • Research grant reviewer for funding bodies, such as British Medical Research Council (MRC), British National Institute for Health Research (NIHR), UK Prostate Action, Prostate Cancer Research Charity, National Cancer Institute of France, International Association of Cancer Research, Hong Kong Research Grants Council.
  • Referee of scientific journals such as Oncogene, J Path, Gene Chromosome Cancer, Br J Cancer, International J Cancer, Carcinogenesis, PloS One, BMC Cancer and Histopathology. Active Member of American Association for Cancer Research.
  • Honorable Professor, Second Military Medical University, Shanghai, China
  • Honorable Professor, Naning Medical University, China
  • Visiting Professor, Zhengzhou University Medical College, China.

News

Our circulating tumour cell (CTC) study results is covered in dozens of national and international media in November 2016 , when it was presented at the NCRI conference; and the updated results is covered in multiple national and international media, including TV, radio, newspaper and online news media in July 2017 , when it was published on clinical Cancer Research.

See other researchers working on:

Cancer and Ageing Genetics Genitourinary Cancer Prostate
This site uses cookies in order to function properly. By continuing to browse, you agree that we can save them on your device. Privacy Policy.